Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.92
(-6.14%)
CNY 42.92
(-6.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.35 Billion CNY | 9.59% |
| 2022 | 3.01 Billion CNY | 8.73% |
| 2021 | 2.77 Billion CNY | -16.71% |
| 2020 | 3.32 Billion CNY | -15.44% |
| 2019 | 3.93 Billion CNY | 14.9% |
| 2018 | 3.42 Billion CNY | 84.61% |
| 2017 | 1.85 Billion CNY | 29.29% |
| 2016 | 1.43 Billion CNY | 18.41% |
| 2015 | 1.21 Billion CNY | 0.15% |
| 2014 | 1.21 Billion CNY | 21.99% |
| 2013 | 992.33 Million CNY | 23.72% |
| 2012 | 802.06 Million CNY | 32.7% |
| 2011 | 604.42 Million CNY | 3.93% |
| 2010 | 581.58 Million CNY | 20.02% |
| 2009 | 484.57 Million CNY | 35.07% |
| 2008 | 358.76 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.06 Billion CNY | 15.46% |
| 2024 Q1 | 742.34 Million CNY | -22.12% |
| 2024 Q2 | 922.01 Million CNY | 24.2% |
| 2023 Q4 | 953.14 Million CNY | -6.02% |
| 2023 FY | 3.3 Billion CNY | 9.59% |
| 2023 Q1 | 623.64 Million CNY | -32.1% |
| 2023 Q2 | 746.05 Million CNY | 19.63% |
| 2023 Q3 | 1.01 Billion CNY | 35.95% |
| 2022 FY | 3.01 Billion CNY | 8.73% |
| 2022 Q2 | 685.33 Million CNY | 21.94% |
| 2022 Q4 | 918.52 Million CNY | 8.13% |
| 2022 Q3 | 849.42 Million CNY | 23.94% |
| 2022 Q1 | 562.01 Million CNY | -34.81% |
| 2021 Q3 | 635.07 Million CNY | 15.87% |
| 2021 Q4 | 862.04 Million CNY | 35.74% |
| 2021 FY | 2.77 Billion CNY | -16.71% |
| 2021 Q1 | 728.11 Million CNY | -23.71% |
| 2021 Q2 | 548.07 Million CNY | -24.73% |
| 2020 Q4 | 954.43 Million CNY | 3.33% |
| 2020 Q1 | 588.68 Million CNY | -38.1% |
| 2020 Q3 | 923.68 Million CNY | 7.06% |
| 2020 FY | 3.32 Billion CNY | -15.44% |
| 2020 Q2 | 862.78 Million CNY | 46.56% |
| 2019 Q1 | 838.99 Million CNY | -37.52% |
| 2019 Q3 | 1.11 Billion CNY | 8.52% |
| 2019 Q4 | 951.03 Million CNY | -14.9% |
| 2019 FY | 3.93 Billion CNY | 14.9% |
| 2019 Q2 | 1.02 Billion CNY | 22.74% |
| 2018 Q2 | 712.25 Million CNY | 48.99% |
| 2018 Q4 | 1.34 Billion CNY | 50.3% |
| 2018 FY | 3.42 Billion CNY | 84.61% |
| 2018 Q1 | 478.05 Million CNY | -11.59% |
| 2018 Q3 | 893.47 Million CNY | 25.44% |
| 2017 Q1 | 272.95 Million CNY | -44.37% |
| 2017 FY | 1.85 Billion CNY | 29.29% |
| 2017 Q2 | 565.05 Million CNY | 107.02% |
| 2017 Q4 | 540.7 Million CNY | 13.25% |
| 2017 Q3 | 477.44 Million CNY | -15.5% |
| 2016 Q3 | 277.76 Million CNY | -43.68% |
| 2016 Q1 | 173.98 Million CNY | -56.23% |
| 2016 Q4 | 490.64 Million CNY | 76.64% |
| 2016 FY | 1.43 Billion CNY | 18.41% |
| 2016 Q2 | 493.21 Million CNY | 183.49% |
| 2015 Q4 | 397.44 Million CNY | 51.78% |
| 2015 Q3 | 261.85 Million CNY | -16.62% |
| 2015 Q2 | 314.05 Million CNY | 31.35% |
| 2015 Q1 | 239.09 Million CNY | -34.3% |
| 2015 FY | 1.21 Billion CNY | 0.15% |
| 2014 Q2 | 307.34 Million CNY | 37.56% |
| 2014 FY | 1.21 Billion CNY | 21.99% |
| 2014 Q4 | 363.94 Million CNY | 15.22% |
| 2014 Q3 | 315.88 Million CNY | 2.78% |
| 2014 Q1 | 223.42 Million CNY | -15.23% |
| 2013 Q2 | 271.33 Million CNY | 47.1% |
| 2013 Q4 | 263.56 Million CNY | -3.45% |
| 2013 FY | 992.33 Million CNY | 23.72% |
| 2013 Q1 | 184.45 Million CNY | -31.43% |
| 2013 Q3 | 272.98 Million CNY | 0.61% |
| 2012 FY | 802.06 Million CNY | 32.7% |
| 2012 Q2 | 212.01 Million CNY | 89.55% |
| 2012 Q3 | 209.19 Million CNY | -1.33% |
| 2012 Q4 | 268.99 Million CNY | 28.59% |
| 2012 Q1 | 111.85 Million CNY | -49.11% |
| 2011 FY | 604.42 Million CNY | 3.93% |
| 2011 Q4 | 219.79 Million CNY | 72.71% |
| 2011 Q3 | 127.26 Million CNY | -28.55% |
| 2011 Q2 | 178.11 Million CNY | 124.71% |
| 2011 Q1 | 79.26 Million CNY | -61.17% |
| 2010 Q3 | 128.58 Million CNY | 0.0% |
| 2010 FY | 581.58 Million CNY | 20.02% |
| 2010 Q4 | 204.11 Million CNY | 58.74% |
| 2009 FY | 484.57 Million CNY | 35.07% |
| 2008 FY | 358.76 Million CNY | 0.0% |